Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Adv Ther. 2023 Jan;40(1):391. doi: 10.1007/s12325-022-02350-8.
No abstract available

Publication types

  • Published Erratum